During the past decade, Fujirebio Diagnostics, Inc conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Fujirebio Diagnostics, Inc" are "Bladder Cancer" (1 trials), "Ovarian Cancer" (1 trials), "Pleural Effusion" (1 trials) and "Pleural Effusion, Malignant" (1 trials). Many other conditions were trialed in "Fujirebio Diagnostics, Inc" in a lesser frequency.

Most popular intervention types in "Fujirebio Diagnostics, Inc" are "Device" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Biomarker Assay (CA125 and HE4)" (1 trials) and "Procedure/Surgery" (1 trials). Other intervention names were less common.

The vast majority of trials in "Fujirebio Diagnostics, Inc" are 2 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Fujirebio Diagnostics, Inc". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Fujirebio Diagnostics, Inc, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Fujirebio Diagnostics, Inc, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".